Last modified: January 9, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
Welcome to Circassia
Circassia is a specialty biopharmaceutical company focused on developing a new class of T-cell vaccines designed to treat allergies and combat organ transplant rejection. The Company’s most advanced allergy T-cell vaccine is entering late-stage development, having successfully completed a number of phase II clinical studies.
The Company was originally founded to develop and commercialise a range of allergy T-cell vaccines based on its proprietary ToleroMune® technology, which has the potential to transform current treatment. With its portfolio of allergy T-cell vaccines progressing rapidly through clinical development, Circassia has broadened its pipeline into other areas where immune system control is essential. These include organ transplant rejection and AutoImmune diseases with initial work focused on rheumatoid arthritis.
The Company is supported by a syndicate of leading institutional and venture capital investors and has completed three successful fundraisings, in January 2007, January 2008 and December 2009. The Company is run by a strong team, which is chaired by Sir Richard Sykes and managed by experienced executives Charles Swingland and Steve Harris. Overall, the management team brings a wealth of experience from major pharmaceutical companies, as well as the biotechnology and specialty pharmaceutical industries.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Circassia Job Trends | Circassia Jobs |
- Biotech Showcase 2010 - Presenting Companies (3 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Circassia has been added to the Ecosystem. |